TSHA
Taysha Gene·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Gap Up
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TSHA
Taysha Gene Therapies, Inc.
A clinical-stage gene therapy company focused on developing treatments for rare genetic diseases
Biological Technology
09/20/2019
09/24/2020
NASDAQ Stock Exchange
73
12-31
Common stock
3000 Pegasus Park Dr. Ste 1430, Dallas, Texas 75247
--
Taysha Gene Therapies, Inc. was originally incorporated under Texas law on September 20, 2019. The Company was converted to a Delaware corporation on February 13, 2020. The Company is a patient-centric gene therapy company dedicated to the development and development of commercialized AAV-based gene therapies for the treatment of rare and large patient populations of central nervous system monogenic diseases.
Earnings Call
Q2/2025
Estimate EPS-0.07
Actual EPS-0.09
Estimate Revenue1.60M
Actual Revenue1.98M
Taysha Gene Therapies' Q2 2025: Key Contradictions in Clinical Trial Endpoints and Regulatory Strategy
Aug 12,2025 01:48
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TSHA has released its 2025 Q3 earnings. EPS was reported at -0.09, versus the expected -0.09, meeting expectations. The chart below visualizes how TSHA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
